| Autor: |
Nogami N; Ehime University Graduate School of Medicine, 454 Shitsukawa, Toon, Ehime, 791-0295, Japan., Nakamura A; Sendai Kousei Hospital, 4-15 Hirosecho, Aoba Ward, Sendai, Miyagi, 980-0873, Japan., Shiraiwa N; Pfizer Japan, 3-22-7 Yoyogi, Shibuya-ku, Tokyo, 151-8589, Japan., Kikkawa H; Pfizer Japan, 3-22-7 Yoyogi, Shibuya-ku, Tokyo, 151-8589, Japan., Emir B; Pfizer Inc., 235 E 42nd St, New York, NY 10017, USA., Wiltshire R; Pfizer Inc., 235 E 42 St, New York, NY 10017, USA., Morise M; Nagoya University Hospital Respiratory Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8560, Japan. |
| Abstrakt: |
Aim: Crizotinib, approved in Japan (2017) for ROS1 -positive NSCLC, has limited real-world data. Materials & methods: Crizotinib monotherapy real-world effectiveness and treatment status were analyzed from claims data (June 2017-March 2021; Japanese Medical Data Vision; 58 patients tested for ROS1 -NSCLC). Results: Median duration of treatment ([DoT]; primary end point), any line: 12.9 months; 22 patients on crizotinib, 23 discontinued, 13 receiving post-crizotinib treatment. 1L (n = 27) median DoT: 13.0 months (95% CI, 4.4-32.0 months); 13 patients on crizotinib; seven discontinued; seven receiving post-crizotinib treatment. 2L (n = 13) median DoT: 14.0 months (95% CI, 4.6-22.2 months); 2L+ (n = 31): nine patients on crizotinib; 16 discontinued; six receiving post-crizotinib treatment. Post-crizotinib treatments (chemotherapy, cancer immunotherapy, anti-VEGF/R) did not affect crizotinib DoT. Conclusion: Data supplement crizotinib's effectiveness in ROS1 -positive NSCLC previously seen in clinical trials/real-world. |
